Positive News Sentiment NASDAQ:SYRS Syros Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.91 -0.05 (-5.21%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$0.91▼$0.9850-Day Range$0.69▼$1.0852-Week Range$0.65▼$5.70Volume221,376 shsAverage Volume762,085 shsMarket Capitalization$57.17 millionP/E RatioN/ADividend YieldN/APrice Target$17.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Syros Pharmaceuticals Stock Forecast (MarketRank)Analyst RatingBuy3.00 Rating ScoreUpside/Downside1,504.4% Upside$14.60 Price TargetShort InterestHealthy7.54% of Float Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.71) to ($1.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.34 out of 5 starsMedical Sector168th out of 1,428 stocksPharmaceutical Preparations Industry73rd out of 682 stocks 3.5 Analyst's Opinion Consensus RatingSyros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.60, Syros Pharmaceuticals has a forecasted upside of 1,504.4% from its current price of $0.91.Amount of Analyst CoverageSyros Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.54% of the float of Syros Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSyros Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Syros Pharmaceuticals has recently decreased by 4.84%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSyros Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyros Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyros Pharmaceuticals has received a 67.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Syros Pharmaceuticals is -1.23. Previous Next 2.7 News and Social Media Coverage News SentimentSyros Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Syros Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for SYRS on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Syros Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -18% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syros Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders11.90% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.18% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Syros Pharmaceuticals are expected to decrease in the coming year, from ($1.71) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syros Pharmaceuticals is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syros Pharmaceuticals is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyros Pharmaceuticals has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SYRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Syros Pharmaceuticals (NASDAQ:SYRS)Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.Read More SYRS Stock News HeadlinesJune 21, 2022 | msn.comSyros Pharmaceuticals Earnings Perspective: Return On Capital EmployedJune 18, 2022 | americanbankingnews.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest UpdateMay 16, 2022 | uk.investing.comSyros Pharmaceuticals Tops Q1 EPS by 7cMay 16, 2022 | finance.yahoo.comSyros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate UpdateMay 13, 2022 | seekingalpha.comSyros Pharmaceuticals Q1 2022 Earnings PreviewMay 13, 2022 | finance.yahoo.comStrength Seen in Immatics (IMTX): Can Its 5.3% Jump Turn into More Strength?May 9, 2022 | finance.yahoo.comSyros to Report First Quarter 2022 Financial Results on Monday, May 16, 2022April 20, 2022 | finance.yahoo.comThese 2 Penny Stocks Could Rally to $15 (Or More), Says Roth CapitalApril 11, 2022 | finance.yahoo.comSyros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical StudiesApril 8, 2022 | finance.yahoo.comSyros Presents New Preclinical Data on its CDK12 Inhibitor Program at American Association for Cancer Research (AACR) Annual Meeting 2022April 1, 2022 | finance.yahoo.comSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 17, 2022 | finance.yahoo.comNew Forecasts: Here's What Analysts Think The Future Holds For Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)March 15, 2022 | finance.yahoo.comSyros Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Key Accomplishments and Upcoming MilestonesMarch 14, 2022 | seekingalpha.comSyros Pharmaceuticals Q4 2021 Earnings PreviewMarch 14, 2022 | benzinga.comSyros Pharmaceuticals's Earnings: A PreviewMarch 9, 2022 | finance.yahoo.comSyros to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 15, 2022March 8, 2022 | finance.yahoo.comSyros to Present New Preclinical Data on its CDK12 Inhibitor Program at the American Association for Cancer Research (AACR) Annual Meeting 2022February 28, 2022 | finance.yahoo.comSyros to Participate in Upcoming Virtual Investor Conferences in MarchFebruary 3, 2022 | nasdaq.comPre-market Movers: BON, FB, BPTS, LSPD, SNAP…February 2, 2022 | seekingalpha.comSyros rises 13% as tamibarotene gets FDA orphan drug status for myelodysplastic syndromeFebruary 2, 2022 | finance.yahoo.comSyros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDSJanuary 12, 2022 | nasdaq.comSyros Pharmaceuticals Inc. Shares Approach 52-Week Low - Market MoverJanuary 11, 2022 | seekingalpha.comSyros outlines clinical updates and 2022 goalsJanuary 10, 2022 | finance.yahoo.comSyros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical CompanyDecember 28, 2021 | finance.yahoo.comHere's Why Syros Pharmaceuticals (NASDAQ:SYRS) Can Manage Its Debt Despite Losing MoneySee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYRS CUSIPN/A CIK1556263 Webwww.syros.com Phone(617) 744-1340FaxN/AEmployees124Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today7/03/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$14.60 High Stock Price Forecast$23.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+1,841.4%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86.56 million Net Margins-403.99% Pretax Margin-403.99% Return on Equity-104.21% Return on Assets-51.51% Debt Debt-to-Equity Ratio0.62 Current Ratio4.22 Quick Ratio4.22 Sales & Book Value Annual Sales$23.49 million Price / Sales2.43 Cash FlowN/A Price / Cash FlowN/A Book Value$1.38 per share Price / Book0.66Miscellaneous Outstanding Shares62,819,000Free Float55,344,000Market Cap$57.17 million OptionableOptionable Beta2.14 Syros Pharmaceuticals Frequently Asked Questions Should I buy or sell Syros Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Syros Pharmaceuticals stock. View analyst ratings for Syros Pharmaceuticals or view top-rated stocks. What is Syros Pharmaceuticals' stock price forecast for 2022? 4 Wall Street analysts have issued 12 month target prices for Syros Pharmaceuticals' stock. Their SYRS stock forecasts range from $10.00 to $23.00. On average, they anticipate Syros Pharmaceuticals' share price to reach $14.60 in the next year. This suggests a possible upside of 1,504.4% from the stock's current price. View analysts' price targets for Syros Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Syros Pharmaceuticals' stock performed in 2022? Syros Pharmaceuticals' stock was trading at $3.26 at the start of the year. Since then, SYRS stock has decreased by 72.1% and is now trading at $0.91. View the best growth stocks for 2022 here. When is Syros Pharmaceuticals' next earnings date? Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Syros Pharmaceuticals. How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) issued its quarterly earnings data on Monday, May, 16th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.08. The firm had revenue of $5.47 million for the quarter, compared to analyst estimates of $4.56 million. Syros Pharmaceuticals had a negative net margin of 403.99% and a negative trailing twelve-month return on equity of 104.21%. During the same quarter in the previous year, the business earned ($0.23) earnings per share. View Syros Pharmaceuticals' earnings history. Who are Syros Pharmaceuticals' key executives? Syros Pharmaceuticals' management team includes the following people: Dr. Nancy A. Simonian M.D., Pres, CEO & Director (Age 61, Pay $939.4k)Dr. Richard A. Young Ph.D., Scientific Founder, Member of Scientific Advisory Board & Director (Age 68, Pay $50k)Mr. Jason Haas, Chief Financial Officer (Age 54, Pay $457.22k)Dr. David A. Roth M.D., Chief Medical Officer (Age 59, Pay $668.12k)Dr. James E. Bradner M.D., Founder (Age 50)Dr. Nathanael S. Gray Ph.D., Scientific Founder & Member of Scientific Advisory BoardMr. Gerald E. Quirk Esq., J.D., Sr. Advisor (Age 54)Dr. Eric R. Olson Ph.D., Chief Scientific Officer (Age 64)Courtney Solberg, Mang. of Corp. Communications and Investor RelationsDr. Christian C. Fritz Ph.D., Head of Biology What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO? 3 employees have rated Syros Pharmaceuticals CEO Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among Syros Pharmaceuticals' employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Syros Pharmaceuticals' key competitors? Some companies that are related to Syros Pharmaceuticals include Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Theseus Pharmaceuticals (THRX), Vaxxinity (VAXX), Provention Bio (PRVB), Kronos Bio (KRON), Viking Therapeutics (VKTX), Rhythm Pharmaceuticals (RYTM), Rigel Pharmaceuticals (RIGL), Impel Pharmaceuticals (IMPL), Nature's Sunshine Products (NATR), Verastem (VSTM), VBI Vaccines (VBIV), Zomedica (ZOM) and Selecta Biosciences (SELB). View all of SYRS's competitors. What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE). When did Syros Pharmaceuticals IPO? (SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Syros Pharmaceuticals' stock symbol? Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS." How do I buy shares of Syros Pharmaceuticals? Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Syros Pharmaceuticals' stock price today? One share of SYRS stock can currently be purchased for approximately $0.91. How much money does Syros Pharmaceuticals make? Syros Pharmaceuticals (NASDAQ:SYRS) has a market capitalization of $57.17 million and generates $23.49 million in revenue each year. The company earns $-86.56 million in net income (profit) each year or ($1.55) on an earnings per share basis. How many employees does Syros Pharmaceuticals have? Syros Pharmaceuticals employs 124 workers across the globe. How can I contact Syros Pharmaceuticals? Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The official website for Syros Pharmaceuticals is www.syros.com. The company can be reached via phone at (617) 744-1340 or via email at hannahd@sternir.com. This page (NASDAQ:SYRS) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
